Equity Profile

BSX

Boston Scientific Corporation

Health CareHealth Care Equipment$72.2B

Feb10Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EST

Company Snapshot

Boston Scientific Corporation (BSX) is a leading global medical technology company that develops and manufactures devices used in various medical fields, including cardiology, urology, and endoscopy. With a market cap of $72 billion, it plays a crucial role in advancing healthcare through innovative solutions that improve patient outcomes.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely watch this quarter.

$0.80

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and increase sales, which is vital for investor confidence.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BSX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+5.92%

Avg Stock Reaction

+0.45%

Last Quarter Recap

In Q1 2026, Boston Scientific reported an EPS of $0.80, matching analyst expectations and resulting in an 8.99% increase in stock price the following day. The company has consistently beaten EPS estimates over the past several quarters, showcasing strong operational performance.

Management Promises & Guidance

Continued focus on innovation in medical devices.
Commitment to expanding market presence in emerging markets.
Enhancing operational efficiency to drive profitability.

Expectations

Wall Street Expectations

Overall, Wall Street is cautiously optimistic about Boston Scientific's upcoming earnings, expecting the company to maintain its track record of beating EPS estimates. However, concerns about revenue growth and market competition may temper enthusiasm.

Bull Case

If Boston Scientific delivers strong EPS and demonstrates robust revenue growth, it could signal a solid recovery in demand for medical devices, boosting investor confidence.

Bear Case

Conversely, if the company fails to meet EPS expectations or shows signs of slowing revenue growth, it could lead to a significant decline in stock price, reflecting market skepticism.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.80

EPS is a key indicator of the company's profitability and financial health, which investors will closely watch this quarter.

Revenue Growth

N/A

Revenue growth reflects the company's ability to expand its market share and increase sales, which is vital for investor confidence.

Market Share in Key Segments

N/A

Understanding market share in critical segments like cardiology and urology will indicate competitive positioning and growth potential.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and how does it compare to past quarters?

Given the company's strong track record of beating EPS estimates, any deviation could significantly impact investor sentiment.

What insights can management provide on revenue growth in key segments?

Understanding revenue trends in critical areas will help gauge the company's competitive position and future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Boston Scientific's ability to leverage its innovative product pipeline, which could drive stronger-than-expected revenue growth this quarter.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating strong operational execution.

Options pricing suggests a lower expected move compared to historical averages, implying potential for a surprise.

Recent insider trading activity shows confidence in the company's future prospects.

Key Risk

If revenue growth exceeds expectations, it could challenge the current cautious sentiment in the market.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Boston Scientific can sustain its growth momentum in a competitive healthcare landscape.

Bull Confirmed If

An EPS of $0.82 or higher would confirm strong operational performance and market demand.

Bear Confirmed If

An EPS below $0.78 could indicate potential challenges in maintaining profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±1.36%

Historical Avg

±5.3%

Pricing cheap

The options market is pricing a relatively modest move of 1.36%, suggesting that investors are anticipating a stable earnings report without significant surprises.

Options are pricing ±1.4% while BSX has averaged ±5.3% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.4%

30d HV

59.7%

Calls (28.2M)P/C Ratio: 0.21Puts (7.0M)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options pricing cheap in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Boston Scientific beats expectations and raises guidance, history suggests the stock could rise by an average of 0.45% on the day.

In-Line / Cautious

If results are in line with expectations but management provides cautious commentary, the stock may experience a muted reaction.

Miss

Should the company miss EPS expectations, history indicates a potential decline in stock price, averaging around 5.27%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

3 buys·2 sells

Members

House + Senate

Est. Notional

$19,005.00–$110,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on new product launches and their expected impact on revenue.
2Management's outlook on market conditions and competitive landscape.
3Updates on operational efficiencies and cost management strategies.
4Any commentary on international market performance and growth opportunities.
5Insights into R&D investments and future innovations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Feb8

HMYReported

Harmony Gold Mining Company Limited

RecapView

Feb8

CNAReported

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely watch this quarter.

$0.80

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and increase sales, which is vital for investor confidence.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BSX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+5.92%

Avg Stock Reaction

+0.45%

Last Quarter Recap

Management Promises & Guidance

Continued focus on innovation in medical devices.
Commitment to expanding market presence in emerging markets.
Enhancing operational efficiency to drive profitability.

Expectations

Wall Street Expectations

Bull Case

If Boston Scientific delivers strong EPS and demonstrates robust revenue growth, it could signal a solid recovery in demand for medical devices, boosting investor confidence.

Bear Case

Conversely, if the company fails to meet EPS expectations or shows signs of slowing revenue growth, it could lead to a significant decline in stock price, reflecting market skepticism.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.80

EPS is a key indicator of the company's profitability and financial health, which investors will closely watch this quarter.

Revenue Growth

N/A

Revenue growth reflects the company's ability to expand its market share and increase sales, which is vital for investor confidence.

Market Share in Key Segments

N/A

Understanding market share in critical segments like cardiology and urology will indicate competitive positioning and growth potential.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and how does it compare to past quarters?

Given the company's strong track record of beating EPS estimates, any deviation could significantly impact investor sentiment.

What insights can management provide on revenue growth in key segments?

Understanding revenue trends in critical areas will help gauge the company's competitive position and future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Boston Scientific's ability to leverage its innovative product pipeline, which could drive stronger-than-expected revenue growth this quarter.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating strong operational execution.

Options pricing suggests a lower expected move compared to historical averages, implying potential for a surprise.

Recent insider trading activity shows confidence in the company's future prospects.

Key Risk

If revenue growth exceeds expectations, it could challenge the current cautious sentiment in the market.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Boston Scientific can sustain its growth momentum in a competitive healthcare landscape.

Bull Confirmed If

An EPS of $0.82 or higher would confirm strong operational performance and market demand.

Bear Confirmed If

An EPS below $0.78 could indicate potential challenges in maintaining profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±1.36%

Historical Avg

±5.3%

Pricing cheap

The options market is pricing a relatively modest move of 1.36%, suggesting that investors are anticipating a stable earnings report without significant surprises.

Options are pricing ±1.4% while BSX has averaged ±5.3% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.4%

30d HV

59.7%

Calls (28.2M)P/C Ratio: 0.21Puts (7.0M)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options pricing cheap in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Boston Scientific beats expectations and raises guidance, history suggests the stock could rise by an average of 0.45% on the day.

In-Line / Cautious

If results are in line with expectations but management provides cautious commentary, the stock may experience a muted reaction.

Miss

Should the company miss EPS expectations, history indicates a potential decline in stock price, averaging around 5.27%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

3 buys·2 sells

Members

House + Senate

Est. Notional

$19,005.00–$110,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on new product launches and their expected impact on revenue.
2Management's outlook on market conditions and competitive landscape.
3Updates on operational efficiencies and cost management strategies.
4Any commentary on international market performance and growth opportunities.
5Insights into R&D investments and future innovations.